
    
      The primary trial objectives are:

      â€¢ Impact on progression-free survival (PFS) when adding MLN9708 to post-transplant
      maintenance treatment with lenalidomide/dexamethasone in patients with multiple myeloma.

      The secondary trial objectives are:

        -  Evaluate development and clinical significance of minimal residual disease (MRD) from
           the time maintenance treatment is initiated, yearly over five years.

        -  Overall survival (OS).

        -  Evaluate the safety and tolerability of the maintenance treatment.
    
  